Mahamaya Lifesciences IPO Subscription Status
Mahamaya Lifesciences IPO received bids for 70,23,600 shares against 41,17,200 offered, an overall subscription of 1.71x at the close of bidding (13 Nov 2025). NII leads at 3.99x.
Last updated · day 3 figures
- Retail
- 1.02x
- NII
- 3.99x
- QIB
- 1.19x
- Total
- 1.71x
Where the demand is
Mahamaya Lifesciences IPO subscription by category
| Category | Shares offered | Shares bid | Amount bid | Subscription |
|---|---|---|---|---|
| QIB | 11,76,000 | 14,01,600 | ₹15.98 Cr | 1.19x |
| NII | 8,82,000 | 35,14,800 | ₹40.07 Cr | 3.99x |
| Retail | 20,59,200 | 21,07,200 | ₹24.02 Cr | 1.02x |
| Total | 41,17,200 | 70,23,600 | ₹80.07 Cr | 1.71x |
* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.
Application-wise breakup and allotment chances
| Category | Lots reserved | Applications | Applied | Chance per application |
|---|---|---|---|---|
| QIB | — | 9 | — | — |
| NII | — | 146 | — | — |
| Retail | — | 878 | — | — |
"All valid" means applications are fewer than the lots reserved, so every valid application should get at least one lot. When applications exceed lots, allottees are picked by computerised lottery and "1 in X" is the rough chance for one application. The real chance is usually a little better: bids below the cut-off price and invalid applications are removed before the lottery.
Mahamaya Lifesciences IPO subscription day-wise
| Category | Day 3 |
|---|---|
| QIB | 1.19x |
| NII | 3.99x |
| Retail | 1.02x |
| Total | 1.71x |
| Total added | 1.71x |
Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.
Mahamaya Lifesciences IPO reservation
| Category | Shares | Share of issue |
|---|---|---|
| Qualified Institutional Buyers | 11,76,000 | 28.56% |
| Non-Institutional Investors | 8,82,000 | 21.42% |
| Retail Individual Investors | 20,59,200 | 50.01% |
| Public issue | 41,17,200 | 100% |
Allotment Chances Note
These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:
- Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
- Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
- Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.
Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.
Mahamaya Lifesciences IPO subscription: FAQs
- What is the overall subscription of Mahamaya Lifesciences IPO?
- Mahamaya Lifesciences IPO is subscribed 1.71x overall as of day 3 (13 November 2025), with bids for 70,23,600 shares against 41,17,200 offered.
- What is the retail subscription of Mahamaya Lifesciences IPO?
- The retail portion is subscribed 1.02x as of day 3 (13 November 2025).
- What is the QIB and NII subscription of Mahamaya Lifesciences IPO?
- QIBs have subscribed 1.19x of their portion, and NIIs 3.99x as of day 3 (13 November 2025).
- How can I check Mahamaya Lifesciences IPO subscription status live?
- This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
- How do I apply for Mahamaya Lifesciences IPO?
- Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 13 November 2025.
Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.